FDA “Breakthrough Therapy” Designations
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Breakthrough status was introduced in FDASIA to facilitate development and review of drugs to treat serious/life-threatening diseases where there is early evidence of a substantial improvement over existing therapies.
You may also be interested in...
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial
Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: